Carisma Therapeutics - CARM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.80
  • Forecasted Upside: 355.96%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.93
▼ -0.05 (-2.53%)

This chart shows the closing price for CARM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Carisma Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CARM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CARM

Analyst Price Target is $8.80
▲ +355.96% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Carisma Therapeutics in the last 3 months. The average price target is $8.80, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 355.96% upside from the last price of $1.93.

This chart shows the closing price for CARM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Carisma Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2024BTIG ResearchInitiated CoverageBuy$6.00Low
4/2/2024HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $9.00Low
11/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
10/3/2023Capital One FinancialInitiated CoverageOverweight$10.00Low
9/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
8/11/2023HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $11.00Low
7/6/2023Evercore ISIInitiated CoverageOutperform$12.00Low
5/31/2023Jefferies Financial GroupUpgradeHold ➝ Buy$7.00Low
5/24/2023HC WainwrightReiterated RatingBuy$10.00Low
4/14/2023Robert W. BairdInitiated CoverageOutperform$10.00Low
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/17/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/16/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 8 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
4/14/2024

Current Sentiment

  • 8 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Carisma Therapeutics logo
Carisma Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $1.93
Low: $1.86
High: $1.99

50 Day Range

MA: $2.29
Low: $1.82
High: $2.60

52 Week Range

Now: $1.93
Low: $1.80
High: $9.77

Volume

217,650 shs

Average Volume

187,551 shs

Market Capitalization

$80.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Carisma Therapeutics?

The following Wall Street analysts have issued stock ratings on Carisma Therapeutics in the last twelve months: BTIG Research, Capital One Financial Co., Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., and Robert W. Baird.
View the latest analyst ratings for CARM.

What is the current price target for Carisma Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Carisma Therapeutics in the last year. Their average twelve-month price target is $8.80, suggesting a possible upside of 356.0%. Evercore ISI has the highest price target set, predicting CARM will reach $12.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $6.00 for Carisma Therapeutics in the next year.
View the latest price targets for CARM.

What is the current consensus analyst rating for Carisma Therapeutics?

Carisma Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CARM will outperform the market and that investors should add to their positions of Carisma Therapeutics.
View the latest ratings for CARM.

What other companies compete with Carisma Therapeutics?

How do I contact Carisma Therapeutics' investor relations team?

Carisma Therapeutics' physical mailing address is 245 1st St Ste 1800, Cambridge, Massachusetts 02142-1292. The company's listed phone number is 617-444-8550 and its investor relations email address is [email protected]. The official website for Carisma Therapeutics is www.sesenbio.com. Learn More about contacing Carisma Therapeutics investor relations.